Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:AVRONASDAQ:ELEVNASDAQ:TSHA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.22-0.8%$1.59$1.20▼$8.70$19.18M1.2987,669 shs56,221 shsAVROAVROBIO$1.19-1.7%$1.28$0.57▼$1.70$53.38M1.22272,822 shs348,448 shsELEVElevation Oncology$3.88-10.2%$4.25$0.36▼$5.89$188.76M1.342.61 million shs658,098 shsTSHATaysha Gene Therapies$2.35-7.1%$2.61$0.50▼$3.89$439.50M0.292.60 million shs794,092 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%-3.15%-20.65%-41.15%-82.98%AVROAVROBIO+0.83%-3.97%-5.47%-9.02%+34.43%ELEVElevation Oncology+6.67%-1.59%-4.00%+74.55%+134.78%TSHATaysha Gene Therapies+2.85%-1.75%-22.15%+72.11%+279.99%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.1555 of 5 stars3.53.00.00.00.60.00.6AVROAVROBIO1.2043 of 5 stars3.03.00.00.00.61.70.6ELEVElevation Oncology2.4148 of 5 stars3.52.00.00.02.82.50.6TSHATaysha Gene Therapies2.0822 of 5 stars4.51.00.00.01.91.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,522.95% UpsideAVROAVROBIO2.00Hold$2.0068.07% UpsideELEVElevation Oncology3.00Buy$7.2586.86% UpsideTSHATaysha Gene Therapies3.00Buy$6.88192.55% UpsideCurrent Analyst RatingsLatest APTO, AVRO, TSHA, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024TSHATaysha Gene TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.004/11/2024TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.004/9/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.004/9/2024TSHATaysha Gene TherapiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$9.004/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/21/2024TSHATaysha Gene TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.003/21/2024TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.003/20/2024TSHATaysha Gene TherapiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.003/20/2024TSHATaysha Gene TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.003/20/2024TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AAVROAVROBION/AN/A$0.28 per share4.19$2.13 per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/ATSHATaysha Gene Therapies$15.45M28.45N/AN/A$0.40 per share5.88Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)ELEVElevation Oncology-$45.70M-$1.53N/AN/AN/AN/A-72.76%-43.15%5/20/2024 (Estimated)TSHATaysha Gene Therapies-$111.57M-$0.67N/AN/AN/A-722.06%N/A-55.72%5/9/2024 (Estimated)Latest APTO, AVRO, TSHA, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/A3/19/2024Q4 2023TSHATaysha Gene TherapiesN/A$0.35+$0.35-$0.22$4.75 million$3.60 million3/6/2024Q4 2023ELEVElevation Oncology-$0.21-$0.19+$0.02-$0.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78AVROAVROBION/A15.7815.78ELEVElevation Oncology0.5521.2221.22TSHATaysha Gene Therapies0.544.084.08OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%AVROAVROBIO62.63%ELEVElevation Oncology83.70%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%AVROAVROBIO9.20%ELEVElevation Oncology14.90%TSHATaysha Gene Therapies2.25%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataAVROAVROBIO1344.86 million40.73 millionOptionableELEVElevation Oncology2948.65 million41.40 millionOptionableTSHATaysha Gene Therapies52187.02 million182.81 millionOptionableAPTO, AVRO, TSHA, and ELEV HeadlinesSourceHeadlineTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Analystsamericanbankingnews.com - April 20 at 5:06 AMCantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)americanbankingnews.com - April 20 at 4:32 AMTaysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Cantor Fitzgeraldmarketbeat.com - April 18 at 10:28 AMCertain Biotech Investors Get an Early Look at Results. Is That Fair?finance.yahoo.com - April 15 at 8:46 AMVanguard Group Inc. Has $16.84 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)marketbeat.com - April 15 at 4:15 AMTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.5% americanbankingnews.com - April 14 at 6:08 AMImpact and Outlook: Taysha Gene Therapies Stock Analysismarkets.businessinsider.com - April 11 at 1:56 PMTaysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLCmarketbeat.com - April 11 at 8:32 AMTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 3%marketbeat.com - April 10 at 12:36 PMTaysha draws bullish view at Piper Sandler on lead assetmsn.com - April 9 at 7:15 PMBuy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue Growthmarkets.businessinsider.com - April 9 at 9:14 AMEvaluating Taysha Gene Therapies: Insights From 7 Financial Analystsmarkets.businessinsider.com - April 9 at 9:14 AMPiper Sandler Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA)marketbeat.com - April 9 at 8:30 AMTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 5 at 8:00 AMTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 5.1%marketbeat.com - April 4 at 2:24 PMTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71marketbeat.com - April 3 at 1:36 PMTaysha Gene Therapies (NASDAQ:TSHA) Trading Down 2.6%marketbeat.com - March 26 at 12:59 PMTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analystsmarketbeat.com - March 26 at 5:01 AMTaysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 21 at 6:44 PMBuy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study Catalystsmarkets.businessinsider.com - March 21 at 8:29 AMTaysha Gene Therapies Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 21 at 8:29 AMBuy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial Healthmarkets.businessinsider.com - March 21 at 3:28 AMTaysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disordermsn.com - March 20 at 5:21 PMBuy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial Stabilitymarkets.businessinsider.com - March 20 at 5:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Elevation OncologyNASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Taysha Gene TherapiesNASDAQ:TSHATaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.